Overview

A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
ImmunoGen, Inc.
Treatments:
Ado-trastuzumab emtansine
Carboplatin
Etoposide
Etoposide phosphate
Lorvotuzumab mertansine
Maytansine